Hallucinogenic mushrooms drug profile
‘Hallucinogenic mushrooms’ is the name commonly given to psychoactive fungi, containing hallucinogenic compounds, most commonly psilocybin and psilocin. At low doses, hallucinogenic drugs have as their primary effects perceptual distortions and alterations of thought, or mood, with the presence of lucid awareness and minimal effects on memory and orientation. Despite their name, the use of hallucinogenic drugs rarely results in true hallucinations. The hallucinogens are a chemically diverse class. Grouping the hallucinogens based on their chemical structure includes, but is not limited to, three major classes: indolealkylamines or tryptamines (e.g. LSD, psilocybine and psilocin), phenethylamines, including mescaline and methylenedioxymethamphetamine (MDMA); and cannabinoids.
Psilocybin (PY, 4-phosphoryloxy-N,N-dimethyltryptamine) is the main psychoactive principle of hallucinogenic mushrooms. After ingestion, psilocybin is converted into the pharmacologically active form psilocin. Psilocin itself is also present in the mushroom, but in smaller amounts. Psilocybin and psilocin are both indolealkylamines and structurally similar to the neurotransmitter serotonin (5-hydroxytryptamine or 5-HT). Besides psilocybin and psilocin, two further tryptamines — baeocystin and norbaeocystin — could also be present but are thought to be less active than the former two.
Psilocybin (psilocybine, psilocibina, psilocybinum, psylosybiini) (CAS-number: 520-52-5) is 4-phosphoryloxy-NN-dimethyltryptamine. According to IUPAC, the fully systematic chemical name is [3-(2-dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate. Psilocybin is the dihydrogen phospate of psilocin. Psilocybin is soluble in water, moderately soluble in methanol and ethanol, and insoluble in most organic solvents. Psilocybin is a prodrug of psilocin, in vivo the molecule is metabolised into psilocin by dephosphorylation.
Molecular structure of psilocybin
Molecular formula: C12H17N204P
Molecular weight: 284.3 g/mol
Psilocin (psilocine, psilocyn) (CAS-number 520-53-6) is 4-hydroxy-NN-dimethyltryptamine (4-OH-DMT) or alternatively 3-(2-dimethylaminoethyl)indol-4-ol. According to IUPAC, the fully systematic chemical name is 3-(2-dimethylaminoethyl)-1H-indol-4-ol. Psilocin is an isomer of bufotenine, it differs only in the position of the hydroxylgroup. Psilocin is relatively unstable in solution. Under alkaline conditions in the presence of oxygen it immediately forms bluish and black degradation products.
Molecular structure of psilocin
Molecular formula: C12H16N20
Molecular weight: 204.3 g/mol
Hallucinogenic mushrooms are available in fresh form, treated/preserved (e.g. deliberately dried, cooked, frozen) or even as dry powders or capsules.
The fungi containing psilocybin and psilocin mainly belong to the genuses Psilocybe, Panaeolus and Copelandia and their number exceeds 50 species. Most of the mushrooms containing psilocybin are small brown or tan mushrooms. In the wild, these mushrooms are easily mistaken for any number of non-psychoactive, inedible, or poisonous mushrooms. This makes them difficult, and potentially hazardous, to identify. Because it is difficult to distinguish non-psilocybin species from the hallucinogenic ones by morphological observation in the wild, psilocybin-containing mushrooms may also be easily ingested unintentionally. Hallucinogenic mushrooms resemble the common store mushroom Agaricus bisporus, although the flesh of Psilocybe mushrooms characteristically turns blue or green when bruised or cut. An identification method based on a genetic approach has been developed.
Psilocin mainly interacts with 5-HT1A, 5-HT2A and 5-HT2C receptor subtypes: it is a mixed receptor agonist. In contrast to LSD, psilocin does not have an effect on the dopamine receptor. Tryptamines and phenethylamine hallucinogens both have a relatively high affinity for serotonin 5-HT2 receptors, but they differ in their affinity for other subtypes of serotonin receptors. The correlation between the relative affinity of hallucinogens for 5-HT2-receptors and their potency as hallucinogens in human beings suggest that an important component of the mechanism of action of these substances is through stimulation of brain 5-HT2-receptors. A primary role for the 5-HT2-receptor in the mechanism of hallucinations is further suggested by the observation that antagonists of the 5-HT2-receptor are effective in blocking the behavioural and electrophysiological effects of hallucinogenic drugs in animals and in man. Although 5HT2-receptors are certainly involved, at present, it is not possible to attribute the psychedelic effects to any single 5-HT receptor subtype.
Behavioural effects are dependent on dose and the individual reaction and sensitivity to psilocybin, previous experiences and the setting. The major effects are related to the central nervous system, but there are also some sympathomimetic effects. The subjective effects, however, may vary greatly between individuals and from one episode of use to the next within the same person. The effects range from mild feelings of relaxation, giddiness, euphoria, visual enhancement (seeing colours brighter), visual disturbances (moving surfaces, waves), to delusions, altered perception of real events, images and faces, or real hallucinations. The sensory distortions may be coupled with restlessness, incoordination, feelings of anxiety, impaired judgement of time or distance, sense of unreality or even depersonalisation. These effects may be termed 'bad trips' by users and can also involve panic reactions and psychosis-like states.
In general, the physiological effects are not significant, but may include dizziness, nausea, weakness, muscle aching, shivering, abdominal pain, dilation of pupils (mydriasis), mild-to-moderate increase in heart rate (tachycardia) and breathing (tachypnea) and elevation of blood pressure. Generally, body temperature remains normal. However, pronounced physical symptoms such as severe stomach pain, persistent vomiting, diarrhoea etc. have been recorded.
Both psilocybin and psilocin can be produced synthetically, but this form of the drug is not often found. Users purchase hallucinogenic mushrooms and by-products from smartshops and on the Internet, or pick them wild. The cubensis varieties are cultivated specifically (mostly in the Netherlands). The types of magic mushrooms most commonly sold by smartshops in the Netherlands are the Psilocybe cubensis varieties.
Online shops sell a variety of hallucinogenic mushroom products ranging from fresh mushrooms to spore prints, spawnbags and growkits. The majority of online shops offer international shipping, although most sites do not ship to countries where sales are prohibited.
Recreational doses range from 1–5 grams of dry mushrooms depending on the species and individual strength of the specimens. Dosages for fresh mushrooms will be approximately 10 times higher (10–50 grams). The material may be eaten raw, boiled in water to make tea, or cooked with other foods to cover its bitter flavour. After ingestion, the psilocybin is enzymatically converted to psilocin. Absorbed from the gastro-intestinal tract, hallucinogenic effects usually occur within 30 minutes of ingestion with a duration of effect of 4–6 hours.
Common names in the English language are: shrooms; magic mushrooms; sacred mushrooms; teonanácatl. Various terms have also been used by users for various forms of psilocybin and psilocin or mushrooms containing these hallucinogens: blue caps; boomers; booms; buttons; caps; champ; fungus; funguys; God's flesh; hombrecitos; las mujercitas; little smoke; Mexican mushroom; mushies; mushroom soup; mushroom tea; mushrooms; musk; pizza toppings; rooms; silly putty; simple Simun; zoomers (Martindale, 2007).
Translations of ‘hallucinogenic mushrooms’ in European languages include:
Bulgarian — ‘магически гъби'; Czech — 'magické houby'; Danish — 'psilocybinsvampe', 'magiske svampe'; Estonian — 'hallutsinogeense toimega seened'; Greek — 'μαγικά μανιτάρια'; French — 'champignons hallucinogènes' or 'champis'; German — 'Psychoaktive Pilze' or 'Zauberpilze'; Hungarian — 'varázsgombák', 'hallucinogén gombák', 'pszilocibingombák'; Italian — 'funghi magici'; Latvian — ‘Halucinogēnās (maģiskās) sēnes'; Lithuanian — 'haliucinogeniniai grybai', 'magiškieji grybai'; Norwegian — 'fleinsopp'; Polish — 'magiczne grzybki', 'grzyby halucynogenne'; Portuguese — 'cogumelos mágicos', 'cogumelos psicadélicos'; Slovakian — 'magické huby'; Slovenian — 'čudeţne gobe'; Spanish — 'hongos alucinógenos', 'hongos lisérgicos', 'honguitos'; Romanian — 'ciuperci halucinogene'; Swedish — 'magiska svampar', 'psykedeliska svampar'.
Psilocin and psilocybin are controlled substances under Schedule I of the United Nations 1971 Convention on Psychotropic Substances. However, the control of the mushrooms that contain these substances is interpreted in many different ways across Europe. Probably this reflects the extent to which they grow freely in certain conditions, and the fact that they appear to be a somewhat regional phenomenon.
For example, in some European countries, the law specifically lists hallucinogenic mushrooms themselves as a controlled substance and forbids their sale or possession. Other countries simply treat the mushrooms as being the controlled substances of psilocin or psilocybin in compound form. Some look at the intent of the act; they ban cultivation, possession or sale only when for the purposes of abuse. Their condition is also considered — fresh mushrooms might not be considered illegal, but prepared or treated mushrooms are illegal — again perhaps reflecting the intent. Interpretation of the term ‘prepared’ or ‘treated’ is a complex matter for the courts. Other countries use a catch-all phrase in the law (‘cultivation of any plant for the purposes of making a psychoactive substance’). Finally, a number of countries remain with unclear legislation, simply as there have been so few cases that have come to court.
In the 1960s, pure synthetic psilocybin (Indocybin®) was marketed by Sandoz for experimental and psychotherapeutic purposes. At present, there are no medical indications for psilocin or psilocybin. Recent research with psilocybin has been reported on the treatment of compulsive disorders in humans.
In the past few years, a growing number of studies using human volunteers have begun to explore the possible therapeutic benefits of drugs such as psilocybin, LSD, DMT, MDMA, ibogaine and ketamine. These studies are looking at psilocybin and other hallucinogens to treat a number of otherwise intractable psychiatric disorders, including chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.
Beck, O., Helander, A., Karlson-Stiber, C., and Stephansson, N. (1998), ‘Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions’, Journal of Analytical Toxicology, Volume 22, No 1, pp. 45–49.
Brown, D. J. (2007), ‘Psychedelic healing?’, Scientific American Mind, December 2007/January 2008, pp. 67–71.
Delgado, P. L. and Moreno, F. A. (1998), ‘Hallucinogens, serotonin and obsessive-compulsive disorder’, Journal of Psychoactive Drugs, Volume 30, No 4, pp. 359–366.
Erowid: Mushrooms, Basics, last modified, 19.07.2007
Date accessed: 4 January 2008.
Hillebrand, J., Olszewski, D., and Sedefov, R. (2006), ‘Hallucinogenic mushrooms: an emerging trend case study’, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon.
Horita, A. and Weber, L. J. (1961), ‘The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates’, Biochemical Pharmacology, Volume 7, pp. 47–54.
Laak, v. d. L. F. J., Wielen, v. d. J. C. A., and Veld in ‘t, P.H. (2002), Psilocybine en psilocine in paddo's. s'Hertogenbosch, SAZD/01/30/21.
Leung, A. Y. and Paul, A. G. (1968), ‘Baeocystin and norbaeocystin: new analogs of psilocybin from Psilocybe baeocystis’, Journal of Pharmaceutical Sciences, Volume 57, No 10, pp. 1667–1671.
Martindale (2007), The complete drug reference, 35th edition, S.C. Sweetman Editor, pp. 2152–2153.
Maruyama, T., Kawahara, N., Yokoyama, K., et al (2006), ‘Phylogenetic relationship of psychoactive fungi based on rRNA gene for a large subunit and their identification using the TaqMan assay (II)’, Forensic Science International, Volume 163, Nos 1–2, pp. 51–58.
McCambridge, J., Winstock, A., Hunt, N., and Mitcheson, L. (2007), ‘5-year trends in use of hallucinogens and other adjunct drugs among UK dance drug users’, European Addiction Research, Volume 13, No 1, pp. 57–64.
O'Brien, C. P. (1996), 'Drug addiction and drug abuse', in Goodman and Guilman's The pharmacological basis of therapeutics, Ninth edition, Joel J. Hardman and Lee Limbird, Editors–in–chief, pp. 557–577.
Peroutka, P. S. (1994), ‘5-Hydroxytryptamine receptor interactions of d-lysergic acid diethylamine’ in 50 years of LSD: Current status and perspectives of hallucinogens, A. Pletscher and D. Ladewig, eds., Parthenon Publishing, New York, pp. 19–26.
Pechnick, R. N. and Ungerleider, J. T. (2005), ‘Hallucinogens’, in Substance abuse: a comprehensive textbook, Fourth edition, Lowinson, J. H., Ruiz, P., Millman, R. B. and Langrod, J. G., Editors, pp. 313–323.
Renfroe, C. L. and Messinger, T. A. (1985), ‘Street drug analysis: an eleven year perspective on illicit drug alteration’, Seminars in Adolescent Medicine, Volume 1, No 4, pp. 247–257.
Repke, D. B., Leslie, D. T., and Guzman, G. (1977), ‘Baeocystin in psilocybe, conocybe and panaeolus’, Lloydia, Volume 40, No 6, pp. 566–578.
Schneider, S. M. (2001), ‘Mushrooms’ in Clinical Toxicology, M. D. Ford et al., eds., W.B. Saunders Company, Philadelphia, pp. 899–908.
Titeler, M., Lyon, R. A., and Glennon, R. A. (1988), ‘Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens’, Psychopharmacology (Berl), Volume 94, No 2, pp. 213–216.
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Babler, A., Vogel, H., and Hell, D. (1998), ‘Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action’, Neuroreport, Volume 9, No 17, pp. 3897–3902.
Neuroscience of psychoactive substance use and dependence, (2004) WHO, Geneva, pp. 104–105.